February
Hayley Shanks, BSc’20 and a third-year PhD student in neuroscience, is studying the clinical trial results of a drug that aims to help Alzheimer's patients by targeting the disease in its early-to-mild stages. Under the supervision of Taylor Schmitz, PhD, assistant professor in Physiology and Pharmacology and researcher with Western’s Brain and Mind Institute, Shanks is analyzing the MRI data results of a drug — known as LM11A31 — that aims to preserve brain cells, including the cholinergic cells involved in memory, learning and attention.
